Holen Sie sich die Stockscreener-App
8.21
1.91%
-0.16
Handel nachbörslich:
8.21
Schlusskurs vom Vortag:
$8.37
Offen:
$8.44
24-Stunden-Volumen:
593.00K
Relative Volume:
0.72
Marktkapitalisierung:
$446.79M
Einnahmen:
$2.85M
Nettoeinkommen (Verlust:
$-143.44M
KGV:
-3.0828
EPS:
-2.6632
Netto-Cashflow:
$-133.44M
1W Leistung:
+2.24%
1M Leistung:
-11.72%
6M Leistung:
-70.68%
1J Leistung:
-10.37%
1-Tages-Spanne:
$8.105
$8.45
1-Wochen-Bereich:
$7.99
$8.69
52-Wochen-Spanne:
$7.25
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Firmenname
Upstream Bio Inc
Sektor
Branche
Telefon
781-208-2466
Adresse
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
8.21 | 455.50M | 2.85M | -143.44M | -133.44M | -2.6632 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
Upstream Bio Inc. (UPB) Q1 2026 Earnings: Narrower Than Expected Loss Reflects Operational DisciplineAI Trading Community - Newser
Upstream Bio (UPB) Q1 2026 Earnings: Narrower-Than-Expected Loss Amid No Revenue; Stock Edges LowerForward EPS Estimate - Newser
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Number of shareholders of Upstream Bio, Inc. – NASDAQ:UPB - TradingView
UPB News | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio Maintained at Buy as Verekitug’s Differentiated Efficacy Supports Steady $42 Price Target - TipRanks
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial of Verekitug Demonstrating Improvement in Asthma Symptom Control in Participants with CRSwNP and Comorbid Asthma at the ATS 2026 International Conference - Sahm
Upstream Bio (UPB) Reveals Promising Phase 2 Trial Results for V - GuruFocus
Upstream Bio, Inc. unveils Phase 2 VIBRANT trial data for verekitug in CRSwNP at ATS2026 - Traders Union
Upstream Bio Announces Positive Phase 2 VIBRANT Trial Results for Verekitug in Chronic Rhinosinusitis with Nasal Polyps and Comorbid Asthma - Quiver Quantitative
Upstream Bio Presents New Data from Phase 2 VIBRANT Trial - GlobeNewswire
New sinus and asthma drug trial slashes steroid use, sinus surgery by 83% - Stock Titan
Upstream Bio, Inc. (UPB) reports Q1 loss, beats revenue estimates - MSN
Upstream Bio (UPB) Surges +3.41%, Nearing $9.54 Resistance 2026-05-17Market Analysis - newser.com
MSN Money - MSN
Upstream Bio lead drug pivotal trial plan follows strong phase 2 data - MSN
UPB Maintains Rating by Mizuho -- Price Target Lowered to $50.00 - GuruFocus
Analysts Offer Insights on Healthcare Companies: Icecure Medical (ICCM) and Upstream Bio, Inc. (UPB) - The Globe and Mail
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $42 to $43 - Moomoo
Mizuho lowers Upstream Bio stock price target on operating spend tweaks - Investing.com Canada
Mizuho Adjusts Price Target on Upstream Bio to $50 From $51, Maintains Outperform Rating - Moomoo
Upstream Bio Reports First Quarter 2026 Financial Results and Recent Business Highlights - Sahm
Upstream Bio, Inc. (UPB) Stock Price Prediction for 2026, 2030-2040 - Traders Union
Upstream Bio : Corporate Presentation May 2026 (May 13, 2026) - marketscreener.com
UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for major respiratory diseases - TradingView
Upstream Bio, Inc. 2026 Q1 Financials and Risk Factors – Nasdaq Global Select Market Filing - Minichart
Upstream Bio Reports Q1 2026 Results and Advances Verekitug Toward Phase 3 Trials for Severe Asthma, CRSwNP, and COPD - Minichart
UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Upstream Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Upstream Bio, Inc. (UPB) Reports Q1 Loss, Beats Revenue Estimates - Yahoo Finance
Upstream Bio, Inc. 1Q 2026: Revenue $1.03M, EPS $(0.75) — 10-Q Summary - TradingView
Upstream Bio reports Q1 2026 net loss $40.6M; cash and short-term investments $294.6M - TradingView
Upstream Bio, Inc. (UPB) Eps Diluted (TTM) - Zacks Investment Research
TradingKey - TradingKey
Upstream Bio, Inc. $UPB Shares Bought by UBS Group AG - MarketBeat
Jennison Associates LLC Makes New Investment in Upstream Bio, Inc. $UPB - MarketBeat
773,148 Shares in Upstream Bio, Inc. $UPB Acquired by Pictet Asset Management Holding SA - MarketBeat
Upstream Bio Inc expected to post a loss of 77 cents a shareEarnings Preview - TradingView
Should I buy Upstream Bio, Inc. (UPB) - Zacks Investment Research
Upstream Bio down despite mid-stage trial win for asthma drug - MSN
Upstream Bio (UPB) price target decreased by 10.31% to 44.37 - MSN
UPB Forecast, Price Target & Analyst Ratings | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Segment Overview and Major Growth Areas in the Upstream Bioprocessing Market - openPR.com
Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsight - GlobeNewswire Inc.
Upstream Bio, Inc. (NASDAQ:UPB) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Upstream Bio (UPB) Stock Bonus Issue (Bearish Sentiment) 2026-04-20Put Flow Alert - Newser
Finanzdaten der Upstream Bio Inc-Aktie (UPB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Upstream Bio Inc-Aktie (UPB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Deykin Aaron | Chief Medical Officer |
Mar 16 '26 |
Sale |
9.29 |
894 |
8,305 |
32,687 |
| Sutherland Everett Rand | Chief Executive Officer |
Mar 16 '26 |
Sale |
9.29 |
2,093 |
19,444 |
72,907 |
| Ambrose Allison | General Counsel |
Mar 16 '26 |
Sale |
9.29 |
475 |
4,413 |
16,525 |
| Houghton Adam | Chief Business Officer |
Mar 16 '26 |
Sale |
9.29 |
699 |
6,494 |
24,301 |
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):